非何杰金氏淋巴瘤治療市場 - 依類型（B 細胞 [瀰漫性大細胞、濾泡細胞、套細胞]、T 細胞 [周邊、皮膚、間變性大細胞]、治療類型（化療、放射、標靶治療））、性別 -全球預測（2024 - 2032）

Non-Hodgkin Lymphoma Therapeutics Market - By Type (B-cell [Diffuse Large, Follicular, Mantle Cell], T-cell [Peripheral, Cutaneous, Anaplastic Large Cell], Therapy Type (Chemotherapy, Radiation, Targeted Therapy)), Gender - Global Forecast (2024 - 2032)

出版日期: 2024年05月30日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於藥物開發的進步和治療選擇的擴大，全球非何杰金氏淋巴瘤治療市場在 2024 年和 2032 年期間複合年成長率將達到 7.4%。標靶治療和聯合治療等藥物創新提高了治療各種淋巴瘤亞型的有效性。這些進步解決了未滿足的醫療需求並提供了個人化的治療方法。隨著新療法的開發和批准，它們為患者和醫療保健提供者提供了更多選擇，有助於增加市場需求和更廣泛的有效治療選擇。

例如，2023年4月，FDA批准了Polivy®（polatuzumab vedotin-piiq）合併Rituxan®（利妥昔單抗）等藥物，標誌著20年來首個新的B細胞淋巴瘤治療方法。此組合可降低 27% 的疾病進展風險。這種新療法可顯著降低疾病進展風險，增強 B 細胞淋巴瘤患者的治療選擇。 20年後推出這樣一種新穎療法，凸顯了市場的創新和成長潛力。它可能會增加對新療法開發的興趣和投資，影響市場動態並擴大治療選擇。

非何杰金氏淋巴瘤治療市場根據類型、治療類型、性別和地區進行分類。

到 2032 年，由於人們對 T 細胞淋巴瘤複雜多樣的亞型的認知不斷增強，T 細胞淋巴瘤細分市場將顯著成長。此細分市場的成長是由對標靶治療的需求以及對 T 細胞淋巴瘤具體機制了解的進展所推動的。持續的研究和開發工作正在創造更有效和個人化的治療方法，解決 T 細胞淋巴瘤帶來的獨特挑戰並改善患者的治療效果，從而推動市場擴張。

由於化療作為主要治療方法的既定作用，其在 2024 年至 2032 年間將大幅成長。化療仍然是治療非何杰金氏淋巴瘤的基石，有效地瞄準和破壞癌細胞。其廣泛的可用藥物和在疾病各個階段已被證實的療效有助於其佔據市場主導地位。隨著正在進行的研究和進步不斷增強化療方案，其在非何杰金氏淋巴瘤治療中的流行和重要性仍然至關重要。

受快速發展的醫療基礎設施和不斷上升的疾病盛行率的推動，亞太地區非何杰金氏淋巴瘤治療產業將在 2032 年之前保持顯著的複合年成長率。該地區不斷擴大的先進治療方法和不斷增加的腫瘤學研究投資促進了這一成長。此外，診斷率的提高和大量患者群體進一步推動了市場擴張。亞太地區在醫療保健方面的進步以及對解決癌症護理需求的承諾使其成為非何杰金氏淋巴瘤治療市場預測的主要貢獻者。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Astellas Pharma US, Inc.
AstraZeneca PLC
Bayer AG
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
GSK plc
F. Hoffmann La-Roche Ltd.
Janssen Pharmaceuticals Inc.
Seagen Inc
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9696

Global Non-Hodgkin Lymphoma Therapeutics Market will record a 7.4% CAGR during 2024 and 2032 due to advancements in drug development and the expansion of treatment options. Innovations in pharmaceuticals, such as targeted therapies and combination treatments, enhance the effectiveness of managing various lymphoma subtypes. These advancements address unmet medical needs and offer personalized treatment approaches. As new therapies are developed and approved, they provide more choices for patients and healthcare providers, contributing to increased market demand and a broader range of effective treatment options.

For instance, in April 2023, the FDA approved Polivy(R) (polatuzumab vedotin-piiq) combined with Rituxan(R) (rituximab) and other drugs, marking the first new B-cell lymphoma treatment in 20 years. This combo reduces disease progression risk by 27%. This new treatment offers a notable reduction in disease progression risk, enhancing therapeutic options for B-cell lymphoma patients. The introduction of such a novel therapy after 20 years underscores the market's potential for innovation and growth. It may drive increased interest and investment in the development of new therapies, influencing market dynamics and expanding treatment choices.

The non-Hodgkin lymphoma therapeutics market is classified based on type, therapy type, gender, and region.

The T-cell lymphomas segment will experience a noteworthy surge by 2032, attributed to the increasing recognition of T-cell lymphomas' complex and diverse subtypes. This segment's growth is driven by the demand for targeted therapies and advancements in understanding the specific mechanisms of T-cell lymphomas. Ongoing research and development efforts are leading to the creation of more effective and personalized treatments, addressing the unique challenges posed by T-cell lymphomas and enhancing patient outcomes, thus driving market expansion.

The chemotherapy segment will witness a substantial uptick between 2024 and 2032, propelled by its established role as a primary treatment method. Chemotherapy remains a cornerstone in managing non-Hodgkin lymphoma, effectively targeting and destroying cancer cells. Its wide range of available drugs and proven efficacy in various stages of the disease contribute to its dominant market position. As ongoing research and advancements continue to enhance chemotherapy regimens, its prevalence and importance in non-Hodgkin lymphoma treatment remain crucial.

Asia Pacific non-Hodgkin lymphoma therapeutics industry will uphold a notable CAGR through 2032, spurred by its rapidly growing healthcare infrastructure and increasing disease prevalence. The region's expanding access to advanced treatments and rising investments in oncology research contribute to this growth. In addition, improving diagnosis rates and a significant patient population further drive market expansion. Asia Pacific's advancements in healthcare and commitment to addressing cancer care needs position it as a primary contributor to the non-Hodgkin lymphoma therapeutics market forecasts.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of Non-Hodgkin lymphoma
  - 3.2.1.2 Expanding investment and R&D activities
  - 3.2.1.3 Approval of new drugs and therapies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 B-cell lymphomas
- 5.2.1 Diffuse large B-cell lymphoma (DLBCL)
- 5.2.2 Follicular lymphoma
- 5.2.3 Mantle cell lymphoma
- 5.2.4 Other B-cell lymphomas
5.3 T-cell lymphoma
- 5.3.1 Peripheral T-cell lymphoma
- 5.3.2 Cutaneous T-cell lymphoma
- 5.3.3 Anaplastic large cell lymphoma
- 5.3.4 Other T-cell lymphomas

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemotherapy
6.3 Targeted therapy
6.4 Radiation therapy
6.5 Other therapy types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Male
7.3 Female

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa